INFORMATION BY CANCER TYPE

Kidney

Cabometyx's Benefit in Kidney Cancer Is Confirmed
BY Jason Harris

Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma. 

Duo Falls Short in Treating Advanced Kidney Cancer
BY Jason Harris
Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.
Promising Combination Moves Into Kidney Cancer
BY Jason M. Broderick
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma. 
Expert Stresses Significance of Genetic Differences in Kidney Cancer
BY Angelica Welch
There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.
Metastatic Kidney Cancer or a Separate Lung Cancer? Expert Urges Patients, Doctors to Learn the Difference
BY Brielle Urciuoli
James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.
Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Kidney Cancer Trial Recommended to Halt
BY Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Combination May Move to the Frontline for Kidney Cancer
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Durable Response Can Remain After Stopping Immunotherapy Treatment for Kidney Cancer
BY Lauren M. Green
A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.
Antibiotics May Compromise Immunotherapy Efficacy in Kidney Cancer
BY Lisa Miller
Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Kidney CURE discussion group.
Search Cancer Drugs & Terms
x